![]() |
||||||
|
||||||
The epidemiology of breast cancer in Maori women in Aotearoa
New Zealand: implications for screening and treatment
Elana Curtis, Craig Wright, Madeleine Wall
The aim of this paper is to describe the incidence and
mortality of breast cancer in Maori and non-Maori women using New Zealand Census
Mortality Study-adjusted estimates to assign ethnicity. The findings of this
paper will help inform future policy development for breast cancer screening and
treatment in New Zealand, with a particular emphasis on the identification and
elimination of ethnic disparities between Maori and non-Maori. This emphasis is
consistent with the Treaty of Waitangi, the indigenous rights of Maori and
current Government policy.1–3
BackgroundAs is seen in many developed
countries, breast cancer is the most common female cancer (apart from skin
cancer) in New Zealand women, and the leading cause of female cancer
deaths.4–6 There is consistent evidence
of Maori vs non-Maori disparities in breast cancer mortality. In New Zealand,
Maori women comprise 15.5% of the female population. In 1997, the overall
age-standardised mortality rate was higher for Maori women (33 per 100,000) than
‘European and Other’ women (22 per
100,000).4
Age-specific analyses show that the mortality rate for Maori
females aged 55–69 years in 1997 was higher than that of ‘European
and Other’ women (118 versus 88 per
100,000).4 Recent New Zealand Census Mortality
Study-adjusted estimates of ethnic-specific mortality found that (for
1996–1999) the Maori breast cancer mortality rate was nearly twice that of
non-Maori non-Pacific women (36 versus 21 per
100,000).7
Estimates of the risk of developing breast cancer for Maori
women in New Zealand are less consistent. Most analyses suggest that Maori women
have a similar age-standardised incidence rate of breast cancer compared to
other women in New Zealand.4,8–11
However, some analyses suggest that Maori breast cancer incidence may be higher
or lower than that of non-Maori, depending on the classification of ethnicity in
numerator and denominator data and study sample
size.4,8,12
The relationship between breast cancer incidence and
mortality rates also varies by ethnicity internationally. In the United States,
African-American women are noted to have a lower overall incidence of breast
cancer than White women, but are disproportionately represented in breast cancer
mortality statistics.13 A ‘black/white
crossover’ in age-specific incidence rates has been documented, where
African American women have a greater risk of developing breast cancer than
White women below the age of 40 years, but a lower risk over age 40
years.14 The reasons for this pattern are not
well understood, and hypotheses include variations in socioeconomic status,
hormonal factors, genetics, nutrition, and healthcare
access.15,16
Methodology and MethodsThis paper uses the
methodological approach of Kaupapa Maori Research to analyse age-specific breast
cancer incidence and mortality data for Maori and non-Maori
women.17,18 Numerator data on breast cancer
incidence and mortality for the years 1996–2000 were obtained from
national cancer registration information (ICD9-CM code 174 Female
Breast)19 and mortality information (ICD9-CM
code 174 Malignant neoplasm of the female
breast).20
Based on the results discussed in an accompanying
paper, ethnicity was assigned as either total or sole Maori and non-Maori by
applying the New Zealand CMS adjustor to both breast cancer registration and
deaths data.18 Denominator data were mean
resident population estimates at the year ended 30 June (sourced from Statistics
New Zealand estimates based on results from the 1996 and 2001 Censuses of
Population and Dwellings).19–21
Denominator ethnicity was identified as non-Maori and
either:
ResultsTotal MaoriA total of
10,424 women were identified from breast cancer registration data for the years
1996 to 2000. Of these women, 843 (8%) were identified as total Maori and 9,581
(92%) as non-Maori. A total of 2,560 women were identified from breast cancer
mortality data for the years 1996–2000.
Of these women, 254 (10%) were identified as total Maori and
2,306 (90%) as non-Maori. Figure 1 presents the NZCMS adjusted age-specific
breast cancer incidence and mortality rates for total Maori and non-Maori women
in New Zealand.
The age-specific incidence rates of breast cancer are
similar for Maori and non-Maori women, particularly in women aged under 55
years. Maori incidence rates drop below non-Maori rates between ages 55 and 64
years. Rates fluctuate from age 65 years, with the Maori incidence rate being
greater than that of non-Maori from age 65 to 74 years, and then lower from age
75 years and over.
Breast cancer mortality rates are generally higher for Maori
than non-Maori, particularly between ages 25 and 59 years. Of note, there is a
drop in the Maori mortality rate between ages 60 and 69 years so that it is
similar to that of non-Maori. Maori mortality then increases and is greater than
non-Maori from age 70 to 84 years, peaking to approximately 180 deaths per
100,000 for ages 75 to 79 years, a rate not seen in non-Maori until age 85 years
and over.
Sole MaoriA total of 10,680 women were
identified from NZCMS breast cancer registration data for the years 1996 to
2000. Of these women, 675 (6%) were identified as sole Maori and 10,005 (94%) as
non-Maori. A total of 2,560 women were identified from NZCMS breast cancer
mortality data for the years 1996–2000. Of these women, 254 (10%) were
identified as sole Maori and 2,306 (90%) as non-Maori.
Figure 2 presents the NZCMS-adjusted age-specific breast
cancer incidence and mortality rates for sole Maori and non-Maori women in New
Zealand for the years 1996 to 2000. Women classified as sole Maori ethnicity
have higher age-specific breast cancer incidence and mortality rates than women
in the total Maori group. NZCMS-adjusted sole Maori mortality peaks at just over
200 breast cancer deaths per 100,000 for women aged 75 to 79 years, slightly
higher than the peak seen for NZCMS-adjusted total Maori women.
Figure 3 presents age-specific breast cancer incidence and
mortality estimates as risk ratios for total and sole Maori and non-Maori women
in New Zealand. Although incidence estimates suggest an elevated risk of breast
cancer in total Maori women compared with non-Maori aged under 50 years, most of
the confidence intervals for the 5-year age groups include one and therefore are
not statistically significant at the 95% level of confidence. Only Maori women
aged 25 to 29 years had a significantly higher risk of developing breast cancer
than non-Maori women, but the numbers in this age group are small.
In contrast, the relative risk of death from breast cancer
is generally greater for total Maori women than non-Maori, apart from the noted
drop between ages 60 and 69 years and 80 years and over. Of note, the Maori vs
non-Maori relative risk estimates for breast cancer mortality in women aged
between 25 and 59 years are statistically significant, and therefore are
unlikely to be due to chance.
Overall the pattern found for sole Maori vs non-Maori risk
ratios are similar to those for total Maori vs non-Maori risk ratios—i.e.
ranging from 1.0–2.2 for sole incidence and 1.1–5.6 for sole
mortality versus 0.7–1.8 for total incidence and 0.9–4.7 for total
mortality. Although the pattern is similar, the risk ratios for sole Maori are
generally higher than those for total Maori.
Summary of key resultsThis analysis found that, despite
similar age-specific breast cancer incidence rates, total Maori women had higher
age-specific mortality rates from breast cancer than non-Maori women,
particularly below the age of 60 years. A similar pattern is seen for sole Maori
age-specific rates, but the mortality rates are even higher than those for total
Maori. Total Maori women aged 65 to 74 years and sole Maori women aged 60 to 79
years had non-significant higher incidence rates of breast cancer than non-Maori
women.
DiscussionThis study represents the first time
a Kaupapa Maori Research analysis of age-specific breast cancer incidence and
mortality has been performed in New Zealand using NZCMS adjustment to compensate
for ethnicity misclassification. Thus, the study provides better quality
ethnicity data on which to base planning for breast cancer screening and
treatment services than has been available previously.
A notable drop in mortality rates for both total and sole
Maori women aged 60 to 69 years was observed. It is unclear why this drop in
mortality occurs, but there are two possible explanations. First, there could be
a ‘cohort effect’ for Maori women associated with reduced breast
cancer mortality due to mortality from other causes, or better access to breast
cancer screening and/or treatment services. Secondly, it may be due to a
fluctuating mortality pattern in older age groups due to the relatively short
study period and modest number of breast cancer events available for analysis.
Therefore, further investigation is required.
Both total and sole Maori women aged 50 to 64 years have a
lower breast cancer incidence rate than non-Maori women. This may be explained
by the aggregation of 5 years’ worth of data that includes 2 years in
which BreastScreen Aotearoa was formally operating: 1998 and 1999. Coverage data
show that non-Maori women were more likely to have been screened in this 2-year
period than Maori women, producing a relatively higher incidence rate for
non-Maori. It is possible that, in the absence of screening, non-Maori incidence
rates between ages 50–64 years would have been similar to or below those
for Maori women. This hypothesis could be investigated by comparing Maori vs
non-Maori incidence rates for non-screen detected cancers only.
There are three broad explanations for the finding that
Maori women have a similar risk of developing breast cancer but a greater risk
of death from breast cancer than non-Maori women. Firstly, Maori women may have
a biologically different disease that is more aggressive than non-Maori leading
to a poorer prognosis. Secondly, Maori women may experience a greater delay in
diagnosis of their breast cancer as a result of differential access to screening
and/or primary health care. Thirdly, Maori women may experience poorer outcomes
from breast cancer treatment associated with differential access to treatment,
patterns of referral, and/or quality of care within the care pathway.
There is currently no conclusive evidence that ethnic
differences in breast cancer mortality reflect biologically different disease
processes occurring for Maori women in comparison to non-Maori.
There is evidence that late diagnosis occurs for Maori
women. Armstrong and Borman reviewed cancer registry data between the years 1972
to 1992 and found that Maori women had higher rates of regional and metastatic
stages than non-Maori women.9 Lawes et al also
reviewed cancer registry data from 1987 to 1994 and found that Maori women were
diagnosed with a more advanced stage of breast cancer than ‘Other’
women.8
Lethaby et al found that (in the Auckland region between
1976 and 1985) Maori women were diagnosed with larger tumours and were more
likely to have metastases at presentation than non-Maori
women.22 Interestingly, they note that a delay
in seeking treatment for initial symptoms did not differ significantly by
ethnicity in their study, implying that the delay was not in presentation but in
diagnosis. Similar findings were found by Newman et al, who noted that Maori
women were significantly more likely to be diagnosed with large tumours (31%),
have 1–3 axillary lymph nodes involved (33%), and have metastases (14%) at
time of presentation than European women (19%, 20%, and 11%
respectively).23
Maori women are also less likely to receive breast cancer
screening services. Between 1999 and 2001, BreastScreen Aotearoa data show that
participation in breast cancer screening was significantly lower for Maori (39%)
and Pacific (34%) women than for non-Maori/non-Pacific women
(59%).24
There is no conclusive information on whether Maori women
may be less likely to receive radiotherapy, chemotherapy and/or surgery
necessary to effectively treat breast cancer once it has been diagnosed. Feek et
al used NZHIS data to estimate five-year relative survival rates for breast
cancer using 1996 to 1999 mortality data.25
They found that only 64% of Maori women survived 5 years after diagnosis
compared with 81% of ‘Other’ women. However, this analysis did not
control for stage of diagnosis, nodal status, or tumour type, so it is not
possible to determine whether the disparity in survival reflects differential
access to treatment.
Lethaby et al reviewed breast cancer survival and controlled
for stage of diagnosis and found that ethnicity was not an independent factor
influencing survival. However, the authors acknowledge that the small sample
size of Maori women included in their study meant that their findings were
inconclusive.22
Investigating where and how ethnic differences may be
occurring on the entire breast cancer care pathway is warranted.
Implications for screeningThe finding of Maori vs non-Maori
disparities in age-specific breast cancer mortality supports the need to deliver
accessible and appropriate breast cancer screening services to Maori women.
Indeed, the successful screening of Maori women has the potential to produce
even greater benefit for Maori women than non-Maori women, particularly for
women under the age of 60 years.
The role of deprivationTo date, international incidence
data and case-control studies have led to the typical portrayal of breast cancer
as a disease of affluence.15 However, there is
increasing recognition that the incidence of breast cancer in poorer countries
and among women of lower socioeconomic status is
‘catching
up’.15 In New Zealand, Ministry of
Health data suggest that breast cancer incidence increases with increasing
deprivation.4 This pattern is not reported for
mortality, although this may be because few data were available for this
analysis (1996/97).4
Given these findings, the relationship between breast cancer
and socioeconomic status appears to be more complex than previously thought, and
analysis of breast cancer epidemiology stratified for deprivation would be
valuable. In addition, ethnic disparities in the distribution of deprivation are
likely to be contributing to Maori disparities in breast cancer screening and
treatment, and should be specifically investigated in future analyses. The
possibility that ethnicity may have an independent effect on whether or not
Maori women receive access to appropriate breast cancer screening and treatments
warrants further investigation, especially as previous New Zealand studies have
documented differential access to health services by
ethnicity.29,30
ConclusionThis study highlights the need to
ensure that breast cancer screening is effectively delivered to Maori women so
that ethnic inequalities are reduced rather than increased by the breast
screening programme. The presence of age-specific disparities in breast cancer
mortality between Maori and non-Maori (despite similar breast cancer incidence
rates) is very concerning. Additional research is required urgently to
understand these disparities, develop effective interventions, and therefore
eliminate their existence.
Author information:
Elana T Curtis (Te Arawa); Public
Health Medicine Specialist, Harkness Fellow in Health Care Policy, Division of
General Internal Medicine, University of California San Francisco, San
Francisco, USA; Craig Wright, Statistics Advisor, Public Health Intelligence,
Ministry of Health, Wellington; Madeleine Wall
(Te Rarawa/Te Aupouri), Clinical Leader
of BreastScreen Aotearoa, National Screening Unit, Ministry of Health,
Wellington
Acknowledgments: We
acknowledge the support received from the National Screening Unit, Public Health
Intelligence, and Te Ropu Rangahau Hauora a Eru Pomare. In particular, we thank
Dr Ashley Bloomfield and Ms Bridget Robson for their assistance in the study
design and analysis, and for helpful comments on earlier drafts of this paper.
In addition, we acknowledge Dr Papaarangi Reid, Ms Donna Cormack, and Dr Martin
Tobias for their contribution to this manuscript. Dr Curtis is also grateful for
support received from the John McCleod Fellowship (Australasian Faculty Public
Health Medicine) that facilitated her to work on this manuscript.
(The authors were employees of the New Zealand Ministry
of Health at the time this paper was written. The views expressed in this paper
are the authors’ own and do not represent the views or policies of the
Ministry of Health. The paper was submitted for publication with the permission
of the Director General of Health.)
Correspondence: Dr
Madeleine Wall, National Screening Unit, Ministry of Health, PO Box 5013,
Wellington. Fax: (04) 495 4484; email: madeleine_wall@moh.govt.nz
References:
|
||||||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |